title: Effects of darunavir/ritonavir-based therapy on metabolic and anthropometric parameters in women and men over 48 weeks.
abstract: Gender-based differences in lipids have been noted in antiretroviral clinical trials. We present the metabolic and anthropometric data from the GRACE (Gender, Race And Clinical Experience) study by gender. Treatment-experienced adults received darunavir/ritonavir (DRV/r) 600/100 mg twice daily, plus a background regimen, over 48 weeks. Fasting blood samples were obtained for lipid, glucose, and insulin measurements at baseline and at weeks 24 and 48/early discontinuation. Anthropometric measurements were taken at baseline and at weeks 12, 24, and 48/discontinuation. The Assessment of Body Change and Distress questionnaire was administered at baseline and regular intervals. Descriptive statistics as well as comparisons using a Wilcoxon rank-sum test are reported. Four hundred twenty-nine patients (women, n=287; men, n=142) enrolled in GRACE; 94 women (32.8%) and 33 men (23.2%) discontinued the trial. Median changes in triglycerides from baseline to week 48 were higher in men (25 mg/dL versus 8 mg/dL; p=0.006); the mean change in triglycerides was higher in men than in women in all racial subgroups. Other lipid and glucose level changes were similar between genders. Anthropometric parameters increased for both genders, with larger increases in women. Patients' perceptions of body changes concurred with physical measurements. The proportion of women who were "satisfied" or "very satisfied" with their bodies increased from 45.2% to 57.8% from baseline to week 48 (p=0.005), while the proportion of men who were "satisfied" or "very satisfied" with their bodies increased from 56.3% to 61.5% from baseline to week 48 (p=0.317). DRV/r-based therapy was associated with small to moderate changes in metabolic parameters, and few between-gender differences were observed. Levels of self-reported, body-related distress improved for women and men over 48 weeks.
authors: University of California, Los Angeles, School of Medicine, Department of Medicine, USA. jscurrier@mednet.ucla.edu
authors: Judith S
authors: JS
authors: Currier
authors: Claudia
authors: C
authors: Martorell
authors: Olayemi
authors: O
authors: Osiyemi
authors: Michael T
authors: MT
authors: Yin
authors: Robert
authors: R
authors: Ryan
authors: Guy
authors: G
authors: De La Rosa
authors: Joseph
authors: J
authors: Mrus
references: J Natl Med Assoc. 2001 Dec;93(12 Suppl):18S-24S
references: 11798060
references: AIDS Behav. 2009 Feb;13(1):53-9
references: 18688706
references: AIDS. 2009 Aug 24;23(13):1679-88
references: 19487905
references: Ann Intern Med. 2010 Sep 21;153(6):349-57
references: 20855799
references: HIV Med. 2001 Apr;2(2):84-8
references: 11737383
references: HIV Clin Trials. 2009 Jan-Feb;10(1):1-12
references: 19362991
references: HIV Med. 2001 Jul;2(3):174-80
references: 11737398
references: J Acquir Immune Defic Syndr. 2003 Sep 1;34(1):58-61
references: 14501794
references: AIDS Res Ther. 2007 May 01;4:8
references: 17472747
references: HIV Clin Trials. 2008 Sep-Oct;9(5):314-23
references: 18977720
references: J Acquir Immune Defic Syndr. 2008 May 1;48(1):35-43
references: 18197118
references: HIV Clin Trials. 2007 Nov-Dec;8(6):371-80
references: 18042502
references: AIDS. 1999 Dec 24;13(18):2493-505
references: 10630518
references: HIV Med. 2006 Mar;7(2):85-98
references: 16420253
references: J Acquir Immune Defic Syndr. 2008 May 1;48(1):44-52
references: 18360291
references: Arch Intern Med. 2000 Jul 10;160(13):2050-6
references: 10888979